We forecast 17% y/y sales growth and an y/y increase in EBIT for Q1, which tends to be SyntheticMR’s seasonally smallest quarter (17% of FY/24E sales). We believe the 3D product, which was launched in the EU and obtained US regulatory clearance during Q1, could become a growth driver ahead, adding to already solid growth momentum. Our DCF-based fair value range of SEK 26-31 is unchanged on largely unchanged estimates.

Link to the analysis